Sera Prognostics (NASDAQ:SERA – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03), FiscalAI reports. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.07 million. Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%.
Here are the key takeaways from Sera Prognostics’ conference call:
- Positive Sentiment: Illinois enacted Medicaid coverage legislation for prescribed proteomic tests and related care management for spontaneous preterm-birth risk, potentially providing access to approximately 50,000 eligible births annually. Sera has begun contracting, credentialing, provider education, and workflow integration, though meaningful utilization is expected to ramp gradually.
- Positive Sentiment: Payer engagement exceeded the company’s 2026 goal, reaching more than 20 opportunities across over 20 states, while Sera launched its fourth commercial partnership and remains on track for five to seven programs. Management expects the pipeline to contribute more meaningfully as opportunities move through implementation and contracting, typically a six- to nine-month process.
- Positive Sentiment: New PRIME data in first-time mothers showed a 22% reduction in NICU admissions and a 30% reduction in severe composite neonatal morbidity, with one NICU admission prevented for every 28 patients screened and treated. The findings and upcoming SMFM presentations are intended to support broader clinical adoption and future guideline inclusion.
- Negative Sentiment: Revenue remained very modest at $30,000, despite month-to-month increases in testing volume, while the net loss widened to $9.1 million from $8.0 million year over year. Sera ended the quarter with $80.3 million in cash and expects it to fund operations through 2029, but near-term commercial conversion remains limited.
- Negative Sentiment: Sera moved its expected European CE-marking submission to the fourth quarter after deciding to conduct additional ELISA assay performance testing to reduce execution risk. Management remains confident in the regulatory plan, but the timing shift delays a potential European commercialization milestone.
Sera Prognostics Trading Up 1.5%
Shares of NASDAQ:SERA traded up $0.03 during mid-day trading on Wednesday, hitting $2.02. 27,687 shares of the company traded hands, compared to its average volume of 52,816. The stock has a 50-day moving average price of $2.00 and a two-hundred day moving average price of $2.13. Sera Prognostics has a 12-month low of $1.56 and a 12-month high of $3.95. The stock has a market cap of $79.10 million, a P/E ratio of -3.11 and a beta of 0.96.
Insiders Place Their Bets
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Lido Advisors LLC purchased a new stake in Sera Prognostics in the 3rd quarter valued at about $68,000. Cetera Investment Advisers bought a new position in shares of Sera Prognostics in the fourth quarter valued at approximately $74,000. Qube Research & Technologies Ltd purchased a new stake in shares of Sera Prognostics during the second quarter valued at approximately $92,000. Two Sigma Investments LP purchased a new stake in shares of Sera Prognostics during the third quarter valued at approximately $97,000. Finally, Barclays PLC lifted its holdings in Sera Prognostics by 267.4% during the fourth quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after acquiring an additional 26,726 shares during the period. 54.64% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research firms have recently commented on SERA. Craig Hallum initiated coverage on Sera Prognostics in a report on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective for the company. Weiss Ratings cut Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $5.50.
Get Our Latest Stock Analysis on SERA
About Sera Prognostics
Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.
Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.
Read More
- Five stocks we like better than Sera Prognostics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
